Table 1.
Patient characteristics
| Patients screened (male/female) (n) | 96 (56/40) | |
| Age (a)* | 63.5 (34–84) | |
| Tumor entity (n) | CRC | 55 |
| CCC | 11 | |
| BCA | 9 | |
| Pancreas CA | 5 | |
| Other (n < 5) | 16 | |
| MRI 1 – first RE (days)* | 1 (0–9) | |
| Site of first RE | Right lobe w/o Segment 4a/4b | 70 |
| Left lobe w/o Segment 4a/4b | 23 | |
| Segments | 3 | |
| Applied activity at first RE (MBq)* | 1027 (340–1900) | |
| MRI 1–MRI 2 (days)* | 34 (20–64) | |
| Untreated Lobe evaluated for AE in MRI 2 | Right lobe w/o Segment 4a/4b | 23 |
| Left lobe w/o Segment 4a/4b | 71 | |
| Segments | 2 | |
| Untreated metastases checked for AE (n) | 765 |
AE abscopal effect, RE radioembolization, * median (range), CRC colorectal cancer, CCC cholangio cellular carcinoma, BCA breast cancer; other: prostate cancer, neuroendocrine carcinoma, lung cancer, anal cancer, cervix cancer, plasmocytoma, endometrial cancer, carcinoid tumor, pharyngeal cancer, stomach cancer, duodenal cancer